CannabisNewsBreaks

FridayMar 09, 2018 3:11 pm

CannabisNewsBreaks – Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Grows in Cannabis Industry through Strategic Investments

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) is a vertically-integrated cannabis company with strategic investments focusing on proven, revenue-generating businesses. An article discussing the company reads: “Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) is a publicly traded Canadian-based company with strategic investments in businesses that are established, revenue- producing players in the medicinal and recreational cannabis market. Liberty Leaf’s focus is to build and support a diversified portfolio of cannabis-sector businesses, including those involved in the cultivation and processing of legal medicinal and recreational cannabis, value-added CBD/THC pet products, and supply-chain products for this…

Continue Reading

FridayMar 09, 2018 3:05 pm

CannabisNewsBreaks – PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Proprietary Sol-gel Formulations May Significantly Improve Bioavailability

Health sciences company PreveCeutical Medical (PRVCF) is engineering a unique Sol-gel CBD-based technology delivery platform to provide direct, controlled pharmacological drug release. This technology could provide a clinical benefit for patients seeking relief for multiple medical indications including pain, inflammation, seizures and neurological disorders. An article discussing the company’s proprietary technology reads: “PreveCeutical’s proprietary Sol-gel formulations begin as a liquid that is administrated into the nose, which then forms a gel as it is warmed in the nasal cavity where it can then be absorbed. This effectively bypasses the stomach and intestines – eliminating first pass metabolism – and may…

Continue Reading

ThursdayMar 08, 2018 3:42 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Innovative Technology is Well-suited in the Cannabis Industry

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has recently developed an oral digestion technology, DehydraTECH™, which is a complementary layer that works with other R&D efforts regarding cannaboids. An article discussing the company reads: “DehydraTECH allows for faster delivery time, lower dosages and shorter treatment regimens. Oral ingestion of the client drug eliminates unhealthy practices of inhalation dosing. It improves the absorption rate, by as much as five to 10 times, of non-steroid anti-inflammatory drugs (NSAIDs), vitamins, cannabinoids and even nicotine. Delivery time, the time it takes from ingestion to payload molecules reaching the bloodstream, is reduced from the 60-90 minutes…

Continue Reading

ThursdayMar 08, 2018 9:56 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Engages VIRTUE to Serve as Agency of Record

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced that it has retained VIRTUE as its agency-of-record. VIRTUE, a creative agency powered by VICE Media, will develop a full rebrand and create sub-brands targeting the medical and adult-use cannabis markets. The agency will also assist the company with an integrated launch strategy for its new brands. “VIRTUE is an award-winning marketing agency with an unwavering commitment to bold ideas. They are the ideal partners to help us to transform the company’s brand and convey the purpose behind our current medical and upcoming adult-use cannabis businesses,” ABcann chief marketing officer Sung…

Continue Reading

WednesdayMar 07, 2018 11:14 am

CannabisNewsBreaks – Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF) Closes $1.5M Private Placement

Hemp cultivation company Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) this morning announced the closing of a non-brokered private placement consisting of 12.5 million units, sold at a price of $0.12 per unit, to raise aggregate gross proceeds of $1.5 million. Each unit consists of one common share of Global Hemp Group and one common share purchase warrant redeemable at a price of $0.15 per common share for a period of five years from closing. Insiders of the company subscribed for an amount of $371,542, or 24.8 percent of the total placement. Per the update, proceeds from…

Continue Reading

WednesdayMar 07, 2018 9:23 am

CannabisNewsBreaks – Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) Inks First Agreement in Retail Investor Program

British Columbia-based cannabis cultivation firm Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) this morning announced that it has signed the first agreement in its retail investor program and welcomes an Okanagan group to the Choom™ brand. Comprised of local investors and business partners, the 'Thompson Okanagan Choom Group' ("TOCG") has exclusive territory rights to open multiple Choom™ branded retail dispensaries in the Thompson-Okanagan region. With decades of combined business experience, TOCG is directed by Debra G Adams, Sherman Dahl, Imre Kovacs and Kent Adams. To view the full press release, visit http://cnw.fm/jP4LY About Choom™ Channeling the spirit of Hawaii in…

Continue Reading

TuesdayMar 06, 2018 3:19 pm

CannabisNewsBreaks – The Green Organic Dutchman Holdings Ltd. Continues Large Scale Cannabis Production as Supply Deficit Approaches

Ultra-low cost organic cannabis producer The Green Organic Dutchman Holdings Ltd., also known as TGOD, is set to reap the benefits from an impending shortage of cannabis in Canada. An article discussing the company reads: “As one of just two producers of organic cannabis and with a million square feet of low cost production planned, the Green Organic Dutchman Holdings Ltd. (“TGOD”) is set to capitalize on Canada’s looming supply shortfall. The company is growing its competitive advantage in a way that appears to run contrary to established dictum by focusing not just on differentiation but also on cost leadership.…

Continue Reading

TuesdayMar 06, 2018 11:16 am

CannabisNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Announces Acquisition of Thrudermic, LLC

Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) this morning announced its acquisition of Thrudermic, LLC, a privately-held North Carolina company. Per the update, Pivot will pay $1.00 for all of the listed and outstanding units of Thrudermic and issue an aggregate of 500,000 shares in the capital of Pivot to Dr. Joseph Borovsky and Dr. Leonid Lurya for their intellectual property portfolio, including patents, good will and know-how in connection with Thrudermic’s Transdermal Nanotechnology. Additionally, Borovsky has been appointed Pivot’s vice president, product formulation, and Lurya has been appointed Pivot’s executive director, product formulation. “Thrudermic is Pivot's…

Continue Reading

TuesdayMar 06, 2018 10:01 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Posts Business Update

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) this morning released an update regarding the company’s recent achievements and plans moving forward. Per the update, the company intends to use its recent financing of $75 million, which brought the company’s cash to over $135 million, to accelerate its growth through a disciplined capital allocation process. Abcann intends to expand its production capacity, focus on branding and product innovation, expand its Harvest Medicine platform to new locations and develop strategic partnerships in the industry. “Over the past five months we have enhanced our leadership team, strengthened our balance sheet, improved operational effectiveness and…

Continue Reading

MondayMar 05, 2018 9:24 am

CannabisNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Successfully Completes C$5M Private Placement of Convertible Debentures

Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) this morning announced the closing of its private placement of convertible debentures for gross proceeds totaling C$5 million. The company issued a total of C$5 million of 10% senior secured convertible debentures which will mature 12 months after the date of their issuance and will be convertible at the option of the holder for a period of 12 months into common shares of the company at a conversion price of C$1.74 per common share, subject to adjustment of the conversion price in certain events. Additionally, Origin Merchant Securities Inc. received a finder’s fee of…

Continue Reading